Medicine & Life Sciences
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
15%
7-hydroxystaurosporine
32%
Acute Myeloid Leukemia
64%
Adaptive Immunity
14%
Adenocarcinoma
17%
Agammaglobulinaemia Tyrosine Kinase
15%
Allogeneic Cells
19%
Antibodies
16%
Antigen Presentation
18%
Antigens
43%
Apoptosis
32%
Azacitidine
17%
B-Cell Chronic Lymphocytic Leukemia
82%
Bispecific Antibodies
16%
Bone Marrow
35%
Bone Marrow Transplantation
14%
Breast Neoplasms
46%
Cathepsin G
17%
Cell Cycle
15%
Cell Line
16%
Cell Proliferation
18%
Cell- and Tissue-Based Therapy
15%
Cellular Immunity
17%
Chimeric Antigen Receptors
23%
Chromatin
14%
Cross-Priming
37%
Cryptococcus
16%
Cyclin E
19%
Cyclins
16%
Cytokines
18%
Cytotoxic T-Lymphocytes
36%
Dendritic Cells
38%
DNA
20%
DNA Damage
18%
DNA Repair
28%
fludarabine
20%
Glioma
32%
Graft vs Host Disease
57%
Growth
21%
Hematologic Neoplasms
16%
Hematopoietic Stem Cell Transplantation
45%
Hematopoietic Stem Cells
34%
Heterografts
17%
HIV
16%
HIV Envelope Protein gp120
17%
HLA Antigens
20%
HLA-A*02:01 antigen
18%
HLA-A2 Antigen
33%
Immunity
29%
Immunotherapy
31%
In Vitro Techniques
21%
Interleukin-7
15%
Isochromosomes
17%
Leukemia
78%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
24%
Leukemia, Myelomonocytic, Chronic
53%
Leukocyte Elastase
43%
Ligands
18%
Lipocalin-2
49%
Lovastatin
15%
Macaca mulatta
44%
Membranes
15%
MicroRNAs
30%
Mucous Membrane
14%
Mutation
15%
Myeloblastin
43%
Myelodysplastic Syndromes
57%
Myeloid Cells
16%
Myeloid Leukemia
30%
Natural Killer T-Cells
28%
Neoplasm Metastasis
20%
Neoplasms
61%
Neutrophils
15%
Nucleosides
35%
Peptides
36%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24%
Primates
16%
Prostatic Neoplasms
15%
Proteins
16%
Recurrence
16%
S Phase
15%
S Phase Cell Cycle Checkpoints
19%
SARS Virus
17%
Stem Cells
28%
Subunit Vaccines
29%
Survival
37%
T-Cell Antigen Receptor
34%
T-Lymphocytes
100%
Therapeutics
41%
thymic stromal lymphopoietin
17%
thymoquinone
18%
Tissue Donors
26%
Trastuzumab
22%
Triple Negative Breast Neoplasms
26%
Tumor Microenvironment
26%
Vaccination
29%
Vaccines
17%
venetoclax
42%